Developing Rapid DNA Sequencing to Accelerate Cancer Research and Care

Cancer is a disease of the genome. In a conversation with Parker Moss, chief partnership officer for Genomics England, and Rosemary Dokos, SVP of product management for Oxford Nanopore Technologies of Oxford Nanopore, we uncover how Nanopore sequencing technology is benefiting from the rapid growth in NVIDIA GPU capacity to deliver comprehensive data analysis that can transform cancer genomics not only in research, but also for clinical accreditation and deployment in the U.K. National Health Service (NHS). Oxford Nanopore and Genomics England are collaborating on a large-scale project to further decode clinical insights from the cancer genome, and to advance operational approaches that bring efficiency gains from more rapid insights into the clinical pathways in the NHS. We'll discuss the challenges and opportunities ahead for accelerating cancer research and clinical practice, and how advances in GPU technology are bringing both scientific and operational benefits that will ultimately lead to improved patient outcomes.